Literature DB >> 9376260

Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro.

K W Colston1, S Y James, E A Ofori-Kuragu, L Binderup, A G Grant.   

Abstract

The GER human pancreatic carcinoma cell line possesses receptors for 1,25-dihydroxyvitamin D3. We report that the vitamin D analogue EB 1089 inhibits the growth of these cells in vitro and when grown as tumour xenografts in immunodeficient mice. Tumour-bearing mice were given EB 1089 at a dose of 5 microg kg(-1) body weight i.p. thrice weekly for 4-6 weeks. Tumour growth was significantly inhibited in treated animals compared with controls in the absence of hypercalcaemia. These findings may have therapeutic implications in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9376260      PMCID: PMC2228083          DOI: 10.1038/bjc.1997.501

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  All-trans-retinoic acid inhibits growth of human pancreatic cancer cell lines.

Authors:  R J Bold; J Ishizuka; C M Townsend; J C Thompson
Journal:  Pancreas       Date:  1996-03       Impact factor: 3.327

2.  Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells.

Authors:  S Y James; A G Mackay; L Binderup; K W Colston
Journal:  J Endocrinol       Date:  1994-06       Impact factor: 4.286

3.  EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells.

Authors:  I S Mathiasen; K W Colston; L Binderup
Journal:  J Steroid Biochem Mol Biol       Date:  1993-09       Impact factor: 4.292

4.  Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group.

Authors:  O M Taylor; E A Benson; M J McMahon
Journal:  Br J Surg       Date:  1993-03       Impact factor: 6.939

5.  Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro.

Authors:  K W Colston; S K Chander; A G Mackay; R C Coombes
Journal:  Biochem Pharmacol       Date:  1992-08-18       Impact factor: 5.858

6.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study.

Authors:  A Wong; A Chan
Journal:  Cancer       Date:  1993-04-01       Impact factor: 6.860

8.  Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells.

Authors:  S Y James; A G Mackay; K W Colston
Journal:  J Mol Endocrinol       Date:  1995-06       Impact factor: 5.098

9.  Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells.

Authors:  K Wosikowski; W Küng; M Hasmann; R Löser; U Eppenberger
Journal:  Int J Cancer       Date:  1993-01-21       Impact factor: 7.396

10.  Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells.

Authors:  G Zugmaier; R Jäger; B Grage; M M Gottardis; K Havemann; C Knabbe
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

View more
  37 in total

1.  Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group.

Authors:  M Porta; N Malats; L Guarner; A Carrato; J Rifà; A Salas; J M Corominas; M Andreu; F X Real
Journal:  J Epidemiol Community Health       Date:  1999-11       Impact factor: 3.710

2.  Plasma 25-hydroxyvitamin D and risk of pancreatic cancer.

Authors:  Brian M Wolpin; Kimmie Ng; Ying Bao; Peter Kraft; Meir J Stampfer; Dominique S Michaud; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; Nader Rifai; Barbara B Cochrane; Jean Wactawski-Wende; Rowan T Chlebowski; Walter C Willett; JoAnn E Manson; Edward L Giovannucci; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-11-15       Impact factor: 4.254

Review 3.  Chemoprevention strategies for pancreatic cancer.

Authors:  Silvia D Stan; Shivendra V Singh; Randall E Brand
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

4.  Vitamin D-binding protein and pancreatic cancer: a nested case-control study.

Authors:  Marina R Piper; D Michal Freedman; Kim Robien; William Kopp; Helen Rager; Ronald L Horst; Rachael Z Stolzenberg-Solomon
Journal:  Am J Clin Nutr       Date:  2015-04-22       Impact factor: 7.045

5.  A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Authors:  Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey
Journal:  J Oncol Pharm Pract       Date:  2014-07-01       Impact factor: 1.809

6.  Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival.

Authors:  Chen Yuan; Zhi Rong Qian; Ana Babic; Vicente Morales-Oyarvide; Douglas A Rubinson; Peter Kraft; Kimmie Ng; Ying Bao; Edward L Giovannucci; Shuji Ogino; Meir J Stampfer; John Michael Gaziano; Howard D Sesso; Julie E Buring; Barbara B Cochrane; Rowan T Chlebowski; Linda G Snetselaar; JoAnn E Manson; Charles S Fuchs; Brian M Wolpin
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

7.  25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).

Authors:  Katherine Van Loon; Kouros Owzar; Chen Jiang; Hedy L Kindler; Mary F Mulcahy; Donna Niedzwiecki; Eileen M O'Reilly; Charles Fuchs; Federico Innocenti; Alan P Venook
Journal:  J Natl Cancer Inst       Date:  2014-08-06       Impact factor: 13.506

8.  Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies.

Authors:  Y Bao; K Ng; B M Wolpin; D S Michaud; E Giovannucci; C S Fuchs
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

Review 9.  Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.

Authors:  Z A Antonello; C Nucera
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

Review 10.  Vitamin D for the prevention and treatment of pancreatic cancer.

Authors:  Kun-Chun Chiang; Tai C Chen
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.